AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked through important technical milestones. AVO is working on the verification and validation phase, prior to LIGHT being used on the first patients to support CE marking. Interim results highlighted the operational and commercial progress that has been made, despite the challenges caused by COVID-19. AVO is holding an investor day on 19 October, where senior management will be available to answer questions.
If you'd like to be introduced to the team at Advanced Oncotherapy, get in touch.
Request a meeting